Effect of GABAB Agonist on Visceral Hyperalgesia in NCCP patientsChinese?

Chinese University of Hong Kong60 enrolled

Overview

The effect of baclofen (GABAB agonist), diltiazem (muscle relaxant) and placebo will be compared in a double-blinded randomized study for the treatment of NCCP. Cerebral cortical, brainstem and spinal evoked potentials before and after treatment will be evaluated. Results of this study will shed lights on pathogenesis and treatment of NCCP in Chinese.We hypothesize that Baclofen alleviates visceral hyperalgesia in NCCP patients by suppressing afferent sensory pathway.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Non-Cardiac Chest Pain

Interventions

Baclofen, DiltiazemDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Consecutive patients with monthly angina-like chest pain and negative coronary angiogram or scintigraphy * Age between 18-70 * Gastroesophageal reflux disease * Psychiatric illness * Cerebrovascular accident * Active peptic ulceration * Heart failure or cardiac bradyarrhythmia * Epilepsy * Pregnancy or lactating female * Previous hypersensitivity to muscle relaxant

Locations (1)

Endoscopy Centre, Prince of Wales Hospital

Hong Kong, China

Outcomes

Primary Outcomes

Esophageal sensory and pain thresholds

Secondary Outcomes

Symptom severity of chest pain at the end of treatment

Evoked potential responses

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.